National Health Investors Stock (NYSE: NHI)

National Health Investors (NYSE:NHI) Stock, Quote.Headers.trade-ideas

National Health Investors

National Health Investors Inc is a housing and medical facility REIT. The company operates through two reportable segments i.e. Real Estate Investments and Senior Housing Operating Portfolio. The Real Estate Investments segment consists of real estate investments and leases, mortgages, and other notes receivables in independent living facilities, assisted living facilities, entrance-fee communities, senior living campuses, skilled nursing facilities, and a hospital. The SHOP segment is comprised of two ventures that own the operations of independent living facilities. The company's revenues are derived from rental income, mortgage and other notes receivable interest income, and resident fees and services.

Le 2 azioni finanziarie da scaricare ad agosto

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ARQT

PGEN

SNOW

TITN

Titan Machinery Reports Weak Preliminary Results, Joins Precigen, Gogoro And Other Big Stocks Moving Lower In Thursday Pre-Market Session

Comparison To The 2008 Crash

Equities

Macro Economic Events

REIT

Sector ETFs

Econ #s

Economics

ETFs

Real Estate

iShares FTSE NAREIT Residential PLUS Capped Index Fund

WELL

Mortgage applications surge 16.8%, refinance activity at highest since 2022. Mortgage-linked stocks reach record levels. Top-performing stocks listed.

Mortgage Applications Rocket By 16.8%, Notch Strongest Weekly Increase In 1.5 Years: &#39;Homebuyers Took The Opportunity To Refinance&#39;

Dividends

Price Target

Analyst Ratings

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a  high dividend payout. 

Wall Street&#39;s Most Accurate Analysts Say Hold These 3 Real Estate Stocks With Over 4% Dividend Yields

National Health Investors, Inc. Common Stock

National Health Investors Inc

NantHealth Inc

In a new SEC filing on September 5, it was revealed that WEBB, Board Member at National Health Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>), executed a significant exercise of company stock options.
What Happened: The latest Form 4 filing on Thursday with the <a href="https://www.sec.gov/Archives/edgar/data/0000877860/000112760224023589//Archives/edgar/data/877860/000112760224023589/0001127602-24-023589-index.htm">U.S. Securities and Exchange Commission</a> uncovered WEBB, Board Member at National Health Investors, exercising stock options for 70,000 shares of NHI. The total transaction was valued at $1,585,550.
The Friday morning update indicates National Health Investors shares down by 0.0%, currently priced at $82.51. At this value, WEBB's 70,000 shares are worth $1,585,550.
<h3>All You Need to Know About National Health Investors</h3>
National Health Investors Inc is a housing and medical facility REIT. The company operates through two reportable segments i.e. Real Estate Investments and Senior Housing Operating Portfolio. The Real Estate Investments segment consists of real estate investments and leases, mortgages, and other notes receivables in independent living facilities, assisted living facilities, entrance-fee communities, senior living campuses, skilled nursing facilities, and a hospital. The SHOP segment is comprised of two ventures that own the operations of independent living facilities. The company's revenues are derived from rental income, mortgage and other notes receivable interest income, and resident fees and services.
<h3>Understanding the Numbers: National Health Investors's Finances</h3>
Revenue Growth: National Health Investors's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 9.11%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Real Estate sector.
Exploring Profitability:
<ul>
<li>
Gross Margin: Achieving a high gross margin of 96.7%, the company performs well in terms of cost management and profitability within its sector.
</li>
<li>
Earnings per Share (EPS): The company excels with an EPS that surpasses the industry average. With a current EPS of 0.81, National Health Investors showcases strong earnings per share.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 0.91, National Health Investors adopts a prudent financial strategy, indicating a balanced approach to debt management.
Evaluating Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a lower-than-average P/E ratio of 28.06, the stock indicates an attractive valuation, potentially presenting a buying opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 10.99 suggests overvaluation in the eyes of investors, considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With a lower-than-industry-average EV/EBITDA ratio of 18.63, National Health Investors presents a potential value opportunity, as investors are paying less for each unit of EBITDA.
</li>
</ul>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Unmasking the Significance of Insider Transactions</h3>
It's important to note that insider transactions alone should not dictate investment decisions, but they can provide valuable insights.
Within the legal framework, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.
However, insider sells may not always signal a bearish view and can be influenced by various factors.
<h3>Deciphering Transaction Codes in Insider Filings</h3>
Digging into the details of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their attention to those taking place in the open market, as outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000877860">Check Out The Full List Of National Health Investors's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

ROBERT WEBB At National Health Investors Decides to Exercises Options Worth $1.59M

Truist Securities analyst Michael Lewis maintains National Health Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>) with a Hold and raises the price target from $65 to $78.

Truist Securities Maintains Hold on National Health Investors, Raises Price Target to $78

On August 27, it was revealed in an SEC filing that James Jobe, Director at National Health Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>) executed a significant exercise of company stock options.
What Happened: A Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000877860/000112760224023009//Archives/edgar/data/877860/000112760224023009/0001127602-24-023009-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday revealed that Jobe, Director at National Health Investors in the Real Estate sector, exercised stock options for 45,000 shares of NHI stock. The exercise price of the options was $54.67 per share.
As of Wednesday morning, National Health Investors shares are up by 0.48%, with a current price of $81.07. This implies that Jobe's 45,000 shares have a value of $1,187,999.
<h3>Get to Know National Health Investors Better</h3>
National Health Investors Inc is a housing and medical facility REIT. The company operates through two reportable segments i.e. Real Estate Investments and Senior Housing Operating Portfolio. The Real Estate Investments segment consists of real estate investments and leases, mortgages, and other notes receivables in independent living facilities, assisted living facilities, entrance-fee communities, senior living campuses, skilled nursing facilities, and a hospital. The SHOP segment is comprised of two ventures that own the operations of independent living facilities. The company's revenues are derived from rental income, mortgage and other notes receivable interest income, and resident fees and services.
<h3>Financial Insights: National Health Investors</h3>
Revenue Growth: National Health Investors's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 9.11%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Real Estate sector.
Profitability Metrics:
<ul>
<li>
Gross Margin: Achieving a high gross margin of 96.7%, the company performs well in terms of cost management and profitability within its sector.
</li>
<li>
Earnings per Share (EPS): National Health Investors's EPS outshines the industry average, indicating a strong bottom-line trend with a current EPS of 0.81.
</li>
</ul>
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.91.
Understanding Financial Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a lower-than-average P/E ratio of 27.44, the stock indicates an attractive valuation, potentially presenting a buying opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 10.75 suggests overvaluation in the eyes of investors, considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With a below-average EV/EBITDA ratio of 18.32, National Health Investors presents an opportunity for value investors. This lower valuation may attract investors seeking undervalued opportunities.
</li>
</ul>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Importance of Insider Transactions</h3>
Investors should view insider transactions as part of a multifaceted analysis and not rely solely on them for decision-making.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Breaking Down the Significance of Transaction Codes</h3>
Delving into transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> typically prioritize those unfolding in the open market, as precisely outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000877860">Check Out The Full List Of National Health Investors's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Decision: James Jobe Exercises Options At National Health Investors For $1.19M

On August 27, it was revealed in an SEC filing that Kevin C. Pascoe, Chief Investment Officer at National Health Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>) executed a significant exercise of company stock options.
What Happened: In an insider options sale disclosed in a Form 4 filing on Tuesday with the <a href="https://www.sec.gov/Archives/edgar/data/0000877860/000112760224023016//Archives/edgar/data/877860/000112760224023016/0001127602-24-023016-index.htm">U.S. Securities and Exchange Commission</a>, Pascoe, Chief Investment Officer at National Health Investors, exercised stock options for 117,167 shares of NHI. The transaction value amounted to $2,267,279.
National Health Investors shares are currently trading down by 0.0%, with a current price of $80.68 as of Wednesday morning. This brings the total value of Pascoe's 117,167 shares to $2,267,279.
<h3>Unveiling the Story Behind National Health Investors</h3>
National Health Investors Inc is a housing and medical facility REIT. The company operates through two reportable segments i.e. Real Estate Investments and Senior Housing Operating Portfolio. The Real Estate Investments segment consists of real estate investments and leases, mortgages, and other notes receivables in independent living facilities, assisted living facilities, entrance-fee communities, senior living campuses, skilled nursing facilities, and a hospital. The SHOP segment is comprised of two ventures that own the operations of independent living facilities. The company's revenues are derived from rental income, mortgage and other notes receivable interest income, and resident fees and services.
<h3>Understanding the Numbers: National Health Investors's Finances</h3>
Revenue Growth: Over the 3 months period, National Health Investors showcased positive performance, achieving a revenue growth rate of 9.11% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Real Estate sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Key Insights into Profitability Metrics:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 96.7%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): The company excels with an EPS that surpasses the industry average. With a current EPS of 0.81, National Health Investors showcases strong earnings per share.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 0.91, National Health Investors adopts a prudent financial strategy, indicating a balanced approach to debt management.
Valuation Metrics: A Closer Look
<ul>
<li>
Price to Earnings (P/E) Ratio: National Health Investors's P/E ratio of 27.44 is below the industry average, suggesting the stock may be undervalued.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 10.75 is above industry norms, reflecting an elevated valuation for National Health Investors's stock and potential overvaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): National Health Investors's EV/EBITDA ratio at 18.32 suggests potential undervaluation, falling below industry averages.
</li>
</ul>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Pay Attention to Insider Transactions</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision. 
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
<h3>Unlocking the Meaning of Transaction Codes</h3>
Taking a closer look at transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, meticulously cataloged in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A signifies a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000877860">Check Out The Full List Of National Health Investors's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Major Exercise Alert: Kevin C. Pascoe Exercises Options Worth $2.27M At National Health Investors

U.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Thursday.
Shares of Titan Machinery Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TITN#NASDAQ">TITN</a>) fell sharply in today's pre-market trading as the company reported weak preliminary <a href="https://www.benzinga.com/quote/TITN/earnings">financial results for the second quarter.</a>
The company said it sees preliminary adjusted earnings of 17 cents per share on revenue of $634 million.
Titan Machinery shares dipped 26.9% to $11.24 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>Precigen, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGEN#NASDAQ">PGEN</a>) shares declined 9% to $1.02 in pre-market trading after posting weak quarterly results.</li>
<li>Gogoro Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GGR#NASDAQ">GGR</a>) fell 6.2% to $1.21 in pre-market trading after reporting second-quarter results.</li>
<li>Snowflake Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) shares declined 4.2% to $121.94 in pre-market trading.</li>
<li>National Health Investors, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>) shares fell 4% to $71.62 in pre-market trading. National Health Investors priced its upsized public offering of 2.4 million common shares at $71.25 per share.</li>
<li>Arcutis Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQT#NASDAQ">ARQT</a>) shares fell 3.8% to $9.22 in pre-market trading following second-quarter results.</li>
<li>EHang Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EH#NASDAQ">EH</a>) declined 3.6% to $11.60 in pre-market trading. EHang Holdings will release its unaudited financial results for the second quarter on Thursday, Aug. 22, before the U.S. market opens.</li>
<li>Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) shares fell 3.3% to $7.32 after gaining around 12% on Wednesday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40368892/jim-cramer-avoid-middle-market-plays-like-golub-capital-buy-mueller-industries-it-is-fan">Jim Cramer: &#8216;Avoid Middle Market Plays&#8217; Like Golub Capital, Buy Mueller Industries — &#8216;It Is Fantastic&#8217;</a></li>
</ul>

The Company has entered into separate forward sale agreements with each of BofA Securities, J.P. Morgan, Wells Fargo Securities and BMO Capital Markets (or their respective affiliates) (the &quot;forward purchasers&quot;) with respect to the shares of common stock covered by the offering. In connection with the forward sale agreements, the forward purchasers or their respective affiliates are expected to borrow and sell to the underwriters all of the shares of common stock that will be delivered in the offering. 
The Company will not receive any proceeds from the sale of shares by the forward purchasers or their respective affiliates.&nbsp;

Reported Earlier, National Health Investors Prices Upsized Public Offering of 2.4M Common Shares At $71.25/Shares

Offerings

National Health Investors Commenced Underwritten Public Offering Of 2M Shares

Mortgage applications skyrocketed by 16.8% in the week ending Aug. 9, according to data released Wednesday by the <a href="https://www.benzinga.com/topic/mortgages">Mortgage Bankers Association</a>.
This impressive increase follows a 6.9% rise in the previous week and represents the largest one-week jump since January 2023. 
The surge comes despite the average contract interest rate for 30-year fixed-rate mortgages with conforming loan balances ($766,550 or less) remaining relatively stable at 6.54%, compared to 6.55% the week before.
<h3 class="wp-block-heading">Refinance Activity Hits Highest Level Since May 2022</h3>
The Refinance Index, which is highly sensitive to interest rate changes, surged by 35% from the previous week, marking a 118% increase compared to the same week last year. 
This sharp rise is the highest weekly gain for the Refinance Index since May 2022. 
Consequently, the refinance share of mortgage activity grew to 48.6% of total applications, up from 41.7% the previous week. Additionally, the share of adjustable-rate mortgage (ARM) applications increased to 7.3% of total applications.
Read Now: <a href="https://www.benzinga.com/economics/macro-economic-events/24/08/40368118/true-us-debt-is-175-trillion-former-coinbase-cto-on-unpayable-crisis">&#8216;True&#8217; US Debt Is $175 Trillion: Former Coinbase CTO On &#8216;Unpayable&#8217; Crisis</a>
Joel Kan, MBA's vice president and deputy chief economist, commented on the data, stating, &#8220;Rates on both 30- and 15-year fixed-rate mortgages decreased for the second consecutive week, and combined with the previous week's rate moves, spurred another strong week for application activity as borrowers with higher rates took the opportunity to refinance.&#8221; 
Kan also highlighted that purchase applications increased by 3%, with modest gains across various loan types, suggesting that prospective homebuyers are gradually returning to the market.
<h3 class="wp-block-heading">Mortgage-Linked Stocks Soar To September 2022 Levels</h3>
The recent surge in mortgage activity has positively impacted mortgage-linked stocks, pushing them to their highest levels since September 2022. 
The iShares Residential and Multisector Real Estate ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REZ#NYSE">REZ</a>) rose 0.3% on Wednesday, putting it on track to close the session at its highest point since September 2022.
Notably, the ETF has posted gains for 12 straight weeks, achieving its longest winning streak since the fund&#8217;s launch in 2007. Additionally, the fund has closed in the green 16 out of the last 17 weeks.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="478" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/14104129/image-1-35-1024x478.png" alt="" class="wp-image-494968" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/14104129/image-1-35-1024x478.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/14104129/image-1-35-300x140.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/14104129/image-1-35-768x358.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/14104129/image-1-35-1536x717.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/14104129/image-1-35.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Image: <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent081424&amp;t=be2bearmibe3na1">Benzinga Pro</a></figcaption></figure>
Below are the top-performing stocks in the REZ ETF year-to-date:
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Name</td>
<td>Ytd Return (%)</td>
</tr>
<tr>
<td>Diversified Healthcare Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DHC#NASDAQ">DHC</a>)</td>
<td>310.64</td>
</tr>
<tr>
<td>National Health Investors, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>)</td>
<td>37.44</td>
</tr>
<tr>
<td>Welltower Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WELL#NYSE">WELL</a>)</td>
<td>33.37</td>
</tr>
<tr>
<td>UMH Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UMH#NYSE">UMH</a>)</td>
<td>31.73</td>
</tr>
<tr>
<td>Independence Realty Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IRT#NYSE">IRT</a>)</td>
<td>31.51</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">As of Aug. 14, 2024 at 10:30 a.m. ET</figcaption></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/08/40365730/july-inflation-rate-falls-more-than-expected-supports-hopes-for-large-fed-rate-cu">July Inflation Rate Falls More Than Expected, Supports Hopes For Large Fed Rate Cuts</a></li>
</ul>
Photo via Shutterstock.

Mortgage Applications Rocket By 16.8%, Notch Strongest Weekly Increase In 1.5 Years: 'Homebuyers Took The Opportunity To Refinance'

Guidance

National Health Investors Raises FY24 Normalized FFO Per Share Outlook From $4.37 - $4.43 To $4.52 - $4.56; Est $4.41

National Health Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>) reported quarterly Normalized FFO of $1.18 per share which beat the analyst consensus estimate of $1.10 by 7.27 percent. This is a 11.32 percent increase over earnings of $1.06 per share from the same period last year. The company reported quarterly sales of $84.970 million which beat the analyst consensus estimate of $81.347 million by 4.45 percent. This is a 9.11 percent increase over sales of $77.876 million the same period last year.

Earnings

Earnings Beats

National Health Investors Q2 2024 Normalized FFO $1.18 Beats $1.10 Estimate, Sales $84.970M Beat $81.347M Estimate

Truist Securities analyst Michael Lewis maintains National Health Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>) with a Hold and raises the price target from $58 to $65.

Truist Securities Maintains Hold on National Health Investors, Raises Price Target to $65

In the latest quarter, 4 analysts provided ratings for National Health Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>), showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $65.0, a high estimate of $69.00, and a low estimate of $58.00. Observing a 7.14% increase, the current average has risen from the previous average price target of $60.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1717099294_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive National Health Investors. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>James Feldman</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$69.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Michael Lewis</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$58.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Richard Anderson</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$66.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Juan Sanabria</td>
<td>BMO Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$67.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to National Health Investors. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of National Health Investors compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of National Health Investors's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into National Health Investors's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NHI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on National Health Investors analyst ratings.</a>
<h2>Unveiling the Story Behind National Health Investors</h2>
National Health Investors Inc is a housing and medical facility REIT. The company operates through two reportable segments i.e. Real Estate Investments and Senior Housing Operating Portfolio. The Real Estate Investments segment consists of real estate investments and leases, mortgages, and other notes receivables in independent living facilities, assisted living facilities, entrance-fee communities, senior living campuses, skilled nursing facilities, and a hospital. The SHOP segment is comprised of two ventures that own the operations of independent living facilities. The company's revenues are derived from rental income, mortgage and other notes receivable interest income, and resident fees and services.
<h3>National Health Investors: A Financial Overview</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: National Health Investors's revenue growth over a period of 3 months has faced challenges. As of 31 March, 2024, the company experienced a revenue decline of approximately -1.06%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Real Estate sector.
Net Margin: National Health Investors's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 37.93%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): National Health Investors's ROE stands out, surpassing industry averages. With an impressive ROE of 2.47%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.24%, the company showcases effective utilization of assets.
Debt Management: National Health Investors's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.91.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About National Health Investors Stock

Wells Fargo analyst James Feldman maintains National Health Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>) with a Overweight and raises the price target from $63 to $69.

Wells Fargo Maintains Overweight on National Health Investors, Raises Price Target to $69

National Health Investors Updates FY24 Normalized FFO From $4.31-$4.37 To $4.37-$4.43

National Health Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>) reported quarterly earnings of $1.12 per share which beat the analyst consensus estimate of $1.06 by 5.66 percent. The company reported quarterly sales of $81.513 million which beat the analyst consensus estimate of $76.851 million by 6.07 percent. This is a 1.06 percent decrease over sales of $82.388 million the same period last year.

National Health Investors Q1 2024 FFO $1.12 Beats $1.06 Estimate, Sales $81.513M Beat $76.851M Estimate

National Health Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated National Health Investors and provided 12-month price targets. The average target is $64.5, accompanied by a high estimate of $69.00 and a low estimate of $58.00. This upward trend is evident, with the current average reflecting a 11.69% increase from the previous average price target of $57.75.
<img src="https://www.benzinga.com/files/images/story/2024/1712253683_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive National Health Investors. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Lewis</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$58.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Richard Anderson</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$66.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Juan Sanabria</td>
<td>BMO Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$67.00</td>
<td>-</td>
</tr>
<tr>
<td>Richard Anderson</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$64.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Connor Siversky</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$63.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Omotayo Okusanya</td>
<td>Deutsche Bank</td>
<td>Announces</td>
<td>Buy</td>
<td>$69.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to National Health Investors. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of National Health Investors compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for National Health Investors's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of National Health Investors's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NHI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on National Health Investors analyst ratings.</a>
<h2>Discovering National Health Investors: A Closer Look</h2>
National Health Investors Inc is a housing and medical facility REIT. The company operates through two reportable segments i.e. Real Estate Investments and Senior Housing Operating Portfolio. The Real Estate Investments segment consists of real estate investments and leases, mortgages, and other notes receivables in independent living facilities, assisted living facilities, entrance-fee communities, senior living campuses, skilled nursing facilities, and a hospital. The SHOP segment is comprised of two ventures that own the operations of independent living facilities. The company's revenues are derived from rental income, mortgage and other notes receivable interest income, and resident fees and services.
<h3>National Health Investors: Financial Performance Dissected</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: National Health Investors's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue growth rate of 12.45%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Real Estate sector.
Net Margin: National Health Investors's net margin is impressive, surpassing industry averages. With a net margin of 40.3%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): National Health Investors's ROE stands out, surpassing industry averages. With an impressive ROE of 2.55%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): National Health Investors's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.28%, the company showcases efficient use of assets and strong financial health.
Debt Management: National Health Investors's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.91.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into National Health Investors Stock: Analyst Perspectives (6 Ratings)

Truist Securities analyst Michael Lewis maintains National Health Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>) with a Hold and raises the price target from $55 to $58.

Truist Securities Maintains Hold on National Health Investors, Raises Price Target to $58

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a <a href="https://www.benzinga.com/yield-investments"> high dividend payout. </a>
Benzinga readers can review the latest analyst takes on&nbsp;their favorite stocks&nbsp;by visiting our&nbsp;<a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings&nbsp;</a>page. Traders can sort through Benzinga&#39;s extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie"> by analyst accuracy </a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the real estate sector.
<h3>PotlatchDeltic Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pch#NASDAQ">PCH</a>)</h3>
<ul>
<li>Dividend Yield: 4.07%</li>
<li>RBC Capital analyst Matthew McKellar reiterated a Sector Perform rating with a price target of $48 on Jan. 31, 2024. This analyst has an accuracy rate of 64%.</li>
<li>Truist Securities analyst Michael Roxland maintained a Hold rating and cut the price target from $51 to $49 on Jan. 31, 2024. This analyst has an accuracy rate of 67%.</li>
<li>Recent News: On Jan. 29, PotlatchDeltic posted better-than-expected quarterly sales.</li>
</ul>
<h3>Healthcare Realty Trust Incorporated (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hr#NYSE">HR</a>)</h3>
<ul>
<li>Dividend Yield: 9.45%</li>
<li>Wedbush analyst Richard Anderson downgraded the stock from Outperform to Neutral and cut the price target from $19 to $15 on Feb. 20, 2024. This analyst has an accuracy rate of 62%.</li>
<li>Citigroup analyst Michael Griffin maintained a Neutral rating and slashed the price target from $19 to $17 on Aug. 22, 2023. This analyst has an accuracy rate of 74%.</li>
<li>Recent News: On Feb. 16, Healthcare Realty Trust posted a decline in sales for the fourth quarter.</li>
</ul>
<h3>National Health Investors, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nhi#NYSE">NHI</a>)</h3>
<ul>
<li>Dividend Yield: 5.94%</li>
<li>Wells Fargo analyst Todd Stender maintained an Equal-Weight rating and raised the price target from $54 to $55 on Nov. 27, 2023. This analyst has an accuracy rate of 68%.</li>
<li>Jefferies analyst Joe Dickstein initiated coverage on the stock with a Hold rating and a price target of $52 on Sept. 20, 2023. This analyst has an accuracy rate of 64%.</li>
<li>Recent News: On Feb. 20, National Health Investors posted better-than-expected quarterly results.</li>
</ul>
&nbsp;
Read More: <a href="https://www.benzinga.com/news/earnings/24/03/37811812/core-main-caleres-and-3-stocks-to-watch-heading-into-tuesday"> Core &amp; Main, Caleres And 3 Stocks To Watch Heading Into Tuesday</a>
&nbsp;

Wall Street's Most Accurate Analysts Say Hold These 3 Real Estate Stocks With Over 4% Dividend Yields

Wedbush analyst Richard Anderson maintains National Health Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>) with a Outperform and raises the price target from $64 to $66.

Wedbush Maintains Outperform on National Health Investors, Raises Price Target to $66

BMO Capital Markets&nbsp;analyst Juan C. Sanabria upgraded&nbsp;National Health Investors, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>) from Market Perform to Outperform,&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/NHI/analyst-ratings" rel="noreferrer noopener">maintaining the price forecast of $67.</a>
Sanabria sees the potential for multiple expansions for the company, with upside to earnings driven primarily by SHOP and acquisitions.
Acquisitions also represent an opportunity with $150 million of debt firepower, given National Health Investors&#8217;&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">low leverage (4.4X net debt/EBITDA).</a>
The analyst keeps a more constructive stance on the company&#8217;s SHOP portfolio given the recent strong 4Q23 occupancy and a solid start to &#8217;24 despite typical seasonal trends.
Sanabria forecasts FY24 SHOP same-store net operating income growth of +30% y/y (guidance 25-30%), above peer&#8217;s guidance.
The midpoint of the company&#8217;s SSNOI guidance conservatively implies only +1.8% growth off fourth quarter 2023 annualized levels, the analyst adds.
After a quiet 2023, Sanabria sees acquisitions picking up amidst financial distress, which aren&#8217;t assumed in guidance.&nbsp;
Overall, the company has a conservative balance sheet, an expanding acquisition opportunity set and a solid management team&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">with an operational background.</a>
The analyst writes that senior housing tenant issues have been addressed, major SNF tenants remain well-positioned, while SHOP has finally turned the corner and risks are fading.
Price Action: NHI shares are trading higher by 0.74% to $59.44 on the last check Tuesday. 
Photo via Shutterstock

Analyst Color

Upgrades

General

Senior Housing Sector Is Reviving, Analyst Forecasts Growth For National Health Investors

The Return Of Volatility

REITs keep reducing NAV discount amid an impending rally

NHI announces public offering of common stock

NHI announces pricing of upsized public offering of common stock

In a report released today, Austin Wurschmidt from KeyBanc maintained a Hold rating on National Health Investors (NHI – Research Report). The compa...

KeyBanc Sticks to Their Hold Rating for National Health Investors (NHI)

Losers And Winners Of REIT Earnings Season

In a report released today, James Feldman from Wells Fargo maintained a Buy rating on National Health Investors (NHI – Research Report), with a pri...

Wells Fargo Sticks to Their Buy Rating for National Health Investors (NHI)

In a report released yesterday, Michael Lewis from Truist Financial maintained a Hold rating on National Health Investors (NHI – Research Report), ...

Truist Financial Sticks to Its Hold Rating for National Health Investors (NHI)

SRET Lost Half Of Its Value And Distribution In Less Than 10 Years

Medical Properties Trust: Expect Shares To Keep Soaring, Trading Below Fair Value

AGNC

AGNCL

AGNCM

AGNCN

AGNCO

AGNCP

BBRE

BLDG

BRSP

BXMT

CHCT

CHMI

CIMN

CLPR

CMTG

COLD

CTRE

CUBE

DFAR

EPRT

EQIX

FREL

GIPR

GIPRW

GLPI

GMRE

GPMT

GQRE

HAUS

HAUZ

HOMZ

IFGL

ILPT

INDS

INVH

IRET

JBGS

JPRE

KBWY

KREF

LAMR

LAND

LANDM

LANDO

LANDP

MFAN

MFAO

MORT

NAIL

NETL

NURE

NXRT

PFFR

PGRE

PLDGP

PPTY

RDOG

REET

REGCO

REGCP

RIET

RITM

ROIC

ROOF

RSPR

SACC

SACH

SBAC

SBRA

SCCC

SCCD

SCCE

SCCF

SCCG

SCHH

SOHO

SOHOB

SOHON

SOHOO

SPRE

SRET

SRVR

STWD

UNIT

USRT

VIOO

VNORP

VRAI

XLRE

Press Releases

NHI Announces Second Quarter 2024 Dividend

NHI Issues Investor Update

NHI Files Supplemental Proxy

Land & Buildings Comments on Half Measures Announced by National Health Investors in Advance of Upcoming Annual Meeting

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

National Health Investors

National Health Investors (NHI) Forecast

National Health Investors (NYSE:NHI) Stock, Quote.Headers.trade-ideas